An awful year came to a head last November, as the pharmaceuticals firm fell nearly 45% in a single session after it lost an appeals court ruling in the US, one that would allow Dr Reddy’s Laboratories Ltd to sell a generic version of Indivior’s all-important opioid treatment Suboxone Film. By the end of 2018 the stock was trading at £1.12, well off of mid-June’s £4.98, all-time peak, and a whopping 72% lower than its £4.07 starting price.
The value-erasing bad news kept coming in 2019, as the US federal appeals court refused to rehear Indivior’s case against Dr Reddy’s Laboratories, wiping another 20% off the stock on February 5th. With Dr Reddy’s allowed to launch its rival product as soon as February 19th, the company is now filing a repeat motion to the US Supreme Courts. Indivior PLC sits at a current trading price of £1.05.
Between those two upsetting updates came the company’s December statement. Indivior said it was aiming to grow sales of new drugs Sublocade and Perseris in order to counter the projected drop in Suboxone revenue, while at some point launching its own generic version of the latter treatment to compete with DRL et al.
Crucially is also said that it was on track to meet its full guidance, as long as its competitors didn’t start to sell the generic treatment before 2019 (they didn’t). Net revenue is expected between $990 million and $1.02 billion, while net income is forecast to come in between $230 million and $255 million. Likely more important will be its forecasts for the current financial year, specifically the extent of the hit to sales of Suboxone.
Indivior PLC(LON:INDV) (LON:INDV) has a consensus rating of ‘Hold’ alongside an average target price of £2.61.
Disclaimer: Spreadex provides an execution only service and the comments above do not constitute (or should not be construed as constituting) investment advice or recommendations, or a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any person placing trades based on their interpretations of the above comments does so entirely at their own risk. Spreadex Ltd is a financial and sports spread betting and sports fixed odds betting firm, which specialises in the personal service and credit area. Founded in 1999, Spreadex is recognised as one of the longest established spread betting firms in the industry with a strong reputation for its high level of customer service and account management.
In relation to spread betting, Spreadex Ltd is authorised and regulated by the Financial Conduct Authority. Spread betting carries a high level of risk to your capital and can result in losses larger than your initial stake/deposit. It may not be suitable for everyone, so please ensure you fully understand the risks involved.